Executives at Big Tech have become adept at navigating the stormy waters of controversy, skillfully defending their companies' interests even before Congress. However, not everyone possesses this knack for managing cross-examination under fire. By borrowing strategies from these corporate leaders, here’s some practical advice on handling controversies effectively, should you find yourself in the hot seat.

Recent studies have found that companies are pushing towards sustainable initiatives that go beyond just what regulations demand. That said, is this what investors want to see?

Investor activism continues to rise from its dip during the pandemic, according to a recent S&P Global Market Intelligence report. Activist investors pose a serious risk - even if their concerns are valid, they still frequently end up destroying a company’s value. To deal with these investors, follow these three tips.

The surge in Lyft’s share price on Tuesday following an astounding typo, stating the company’s adjusted EBITDA margin expansion was 500 basis points instead of 50. The false metric caused a buying frenzy among trading bots, which calculated the stock price as seriously undervalued. It shows the immense power these automated trading algorithms have in the market and how havoc they can wreak.

The Chiefs back-to-back Super Bowl victories show that being a champion in any discipline requires smart and consistent decision making. We took a few pages from their playbook and put together 3 tips on how to be an Investor Brand Champ.

23andMe is considering splitting up its business into two entities—one focused on DNA-testing and the other on drug development—after the stock slid by as much as 10% after second quarter 2024 earnings. The proposed strategic shift arrives at a pivotal moment for 23andMe, a company that once boasted a market cap exceeding $6 billion and now trades for pennies as it faces a Nasdaq delisting.

The problem runs deeper than just missing quarterly forecasts. The split is being seen as a last-ditch attempt to regain stability in a market that has quickly soured on its business model. The rapid decline in share price highlights the volatile nature of the tech and biotech sectors as well as the critical need for agility in strategic planning. All told, there’s been a significant loss of trust in the company's leadership team triggering a massive crisis of confidence.